Drug Profile
K 312
Alternative Names: K-312Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Kowa Pharmaceutical
- Class Antihyperlipidaemics; Small molecules
- Mechanism of Action Cholesterol ester transfer protein inhibitors; PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dyslipidaemias; Hyperlipidaemia
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in USA (PO)
- 23 Jan 2018 K 312 is still in phase I trials for Dyslipidaemia in USA (PO) (Kowa pipeline, January 2018)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Dyslipidaemias(In volunteers) in USA (PO)